Filtered By:
Management: Budgets

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 83 results found since Jan 2013.

Budget Impact Analysis of Cerebrolysin In The Treatment of Acute Ischemic Stroke of Moderate and Severe Degrees of Severity In The Russian Federation
To conduct budget impact analysis of neurotrophic and neuroprotective drug cerebrolysin with standard therapy compared to standard therapy only of ischemic stroke of moderate and severe degrees of severity according to the Russian healthcare system.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: A Kulikov, G Abdrashitova Source Type: research

Budget Impact Analysis of The Use of Alteplase In The Treatment of Acute Ischaemic Stroke In Mexico
To estimate the economic impact of the use of alteplase versus best supportive care (BSC) in patients with acute ischemic stroke in Mexico.
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: JL Huicochea-Bartelt, E Palacios, L Zapata, S Herran Tags: CARDIOVASCULAR DISORDERS – Cost Studies Source Type: research

Pharmacoeconomic Analysis of Naftidrofuryl for Ischemic Stroke Treatment
Perform the pharmacoeconomic analysis of including naftidrofuryl into the Russian standards for treatment and rehabilitation of patients suffering from ischemic stroke by means of performing Cost Minimization Analysis (CMA) and Budget Impact Analysis (BIA).
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: D Belousov, A Cheberda Source Type: research

Budget Impact of Alteplase In Treatment of Acute Ischemic Stroke In Turkey
Cerebrovascular diseases are the sixth cause of total DALYs in Turkey and the Turkish Social Security Institution (SSI) faces a challenge on reimbursement decisions for treatment. Alteplase is a recombinant human tissue plasminogen activator indicated for treatment of acute ischemic stroke (AIS). Clinical trials have proved efficacy in reducing 90-day disability measured by the Modified Rankin Score (mRS) if administered within 4,5 hours of onset of symptoms. The agent is used as an addition to Standard of Care (SoC).
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: M Tatar, A Şentürk, E Tetik, L Yıldız, J Cheynel Source Type: research

Budget Impact of Post-Stroke Dysphagia: Database Analyses of Hospital Discharges In France And Switzerland
Oropharyngeal dysphagia is prevalent in hospitalized post-stroke patients and is associated with increased mortality and comorbidities. The aim of our analysis was to evaluate the impact of dysphagia on Length of Hospital Stay (LOS) and costs. The hospital perspective was used to assess costs.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: N Muehlemann, L de L éotoing, B Jouaneton, J Fernandes, M Arnold, G Kägi Source Type: research

EE460 A Budget Impact Model to Evaluate the Economic Impact of Treating Walking Impairment in Chronic Stroke, A US Perspective
MR-001 is an investigational, at-home rehabilitation system designed to improve walking and ambulation status in adults with chronic stroke. A budget impact model (BIM) was developed to evaluate the economic impact associated with the reimbursement of MR-001 from a US payer perspective.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: S. Kane, N. Jayawardena, M. Bourque, J. Lavanture, H. Roberts Source Type: research

MassDevice.com +5 | The top 5 medtech stories for September 15, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. FDA cuts could threaten medtech innovation: Here’s why The Trump administration’s proposed federal budget could hurt the speed and quality of FDA review times, says a top expert at Musculoskeletal Clinical Regulatory Advise...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

4 Key Insights When Raising Money for Your Medtech Startup: Interview with Bruce Shook, CEO of Intact Vascular
Welcome to the Medsider interview series, a regular feature at MassDevice. All interviews are conducted by Scott Nelson, Founder of Medsider and Group Director for WCG. We hope you enjoy them! Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression. Previously, Shook was Co-founder, Director, President, an...
Source: Mass Device - February 27, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Blog medsider Source Type: news

Survey for people benefiting from personal health budgets
The 2019-20 CQUIN scheme includes a CQUIN for providers of community stroke services, under the NHS standard contract, to undertake six month post stroke reviews and record these on SSNAP (Sentinel Stroke National Audit Programme).
Source: NHS Networks - April 15, 2019 Category: UK Health Source Type: news

The impact of global budgeting on treatment intensity and outcomes
Abstract This paper investigates the effects of global budgets on the amount of resources devoted to cardio-cerebrovascular disease patients by hospitals of different ownership types and these patients’ outcomes. Theoretical models predict that hospitals have financial incentives to increase the quantity of treatments applied to patients. This is especially true for for-profit hospitals. If that’s the case, it is important to examine whether the increase in treatment quantity is translated into better treatment outcomes. Our analyses take advantage of the National Health Insurance of Taiwan’s implementation...
Source: International Journal of Health Care Finance and Economics - September 30, 2014 Category: Health Management Source Type: research

Death by a Thousand Cuts
It is likely that you don't realize what your state and our nation have lost in economic terms and research productivity as a result of recent cuts in the federal budget and budget instability brought on by a failure of Congress to pass a budget in a timely manner. Although some members of Congress strongly support increased funding for U.S. research, others argue that the time has come for the cost of basic biomedical research to be borne by industry and philanthropy. Those who make that argument either ignore, or are unaware, that this experiment has already been tried -- unsuccessfully. Nearly 80 years ago, Louisiana ...
Source: Science - The Huffington Post - October 24, 2014 Category: Science Source Type: news

Budget Impact of Left Atrial Appendage Occulusion in Patients with Atrial Fibrillation Contraindicated to Anticoagulation
Stroke is a leading public health problem in terms of mortality and economic burden in Korea. Anticoagulants are the mainstay for ischemic stroke prevention in atrial fibrillation (AF), but many patients have contraindications to these drugs. A number of catheter-based left atrial appendage occlusion (LAAO) devices devised to eliminate the major cause of thromboembolism in AF patients have been commercialized in Europe but are not yet available in Korea. The purpose of this study is to perform a budget impact analysis of LAAO in patients with AF contraindicated to anticoagulation.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: J.W. Park, M. Koullick, E. Han Tags: CARDIOVASCULAR DISORDERS - Cost Studies Source Type: research

5 Healthy Eating Habits To Adopt This Year
By Cynthia Sass, MPH, RD Nutrition is a hot topic these days, yet many of my clients still struggle with consistently following through with "the basics," and the stats show that missing the mark on many healthy habits is the norm. For example, the median daily intake of produce for U.S. adults is 1.1 servings of fruit and 1.6 servings of veggies, far below the minimum recommended five daily servings. If you're going to set just one goal for 2015, I think eating more produce should be it, but I've also listed four others below. I know you've heard them before, but they are without a doubt the most tried-and-true, impactf...
Source: Healthy Living - The Huffington Post - January 11, 2015 Category: Consumer Health News Source Type: news

Socioeconomic factors relating to diabetes and its management in India / 印度与糖尿病及其治疗相关的社会经济因素
Abstract Diabetes is an escalating problem in India and has major socioeconomic dimensions. Rapid dietary changes coupled with decreased levels of physical activity have resulted in increases in obesity and diabetes in rural and semi‐urban areas, as well as in urban‐based people living in resettlement colonies. Increasing risk has also been recorded in those who suffered from poor childhood nutrition and in rural‐to‐urban migrants. Social inequity manifests in disparities in socioeconomic status (SES), place of residence, education, gender, and level of awareness and affects prevention, care, and management. All th...
Source: Journal of Diabetes - July 30, 2015 Category: Endocrinology Authors: Usha Shrivastava, Anoop Misra, Rajeev Gupta, Vijay Viswanathan Tags: Review Article Source Type: research

The Uptake of Non-Vitamin K Oral Anticoagulants in Ireland: Balancing Cost-Effectiveness Analysis and Budget Impact
For many years vitamin K antagonists (usually warfarin) were the only oral anticoagulants available to reduce stroke risk in Atrial fibrillation (AF). The non-vitamin K oral anticoagulants (NOACs) were first licensed in Ireland for stroke prevention in non-valvular AF with the approval of dabigatran etexilate in 2011. Rivaroxaban followed later that year, apixaban in 2013 and edoxaban in 2015. The National Centre for Pharmacoeconomics (NCPE) reviewed all the NOACs for cost-effectiveness prior to reimbursement approval in Ireland.
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: M Barry, S Clarke, N Geraghty Source Type: research